Send to

Choose Destination
Leuk Lymphoma. 2002 May;43(5):1075-7.

The CD19 compartment in myeloma includes a population of clonal cells persistent after high-dose treatment.

Author information

Department of Hematology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.


Peripheral blood-localized clonal cells in patients with multiple myeloma (MM) have been reported to be insensitive to chemotherapy and it has been suggested that these cells may include the proliferative compartment in myeloma. In this study, circulating clonal CD19+ cells levels were determined in 10 patients with MM by performing patient-specific RT-PCR on single flow-sorted CD19+ cells. A variable proportion of CD+ cells being clonal were identified (0.101-6.130%, mean 1.019%). In 10/10 MM patients clonal CD19+ cells were found after high-dose treatment and peripheral blood stem cell transplantation. In conclusion, CD19+ clonal cells include a population of cells persistent after high dose chemotherapy that may be responsible for relapse.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center